Cardiol Therapeutics Inc（CRDL）财务数据CRDLCardiol Therapeutics Inc

Evaluating the bottom line, Cardiol Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -190.18%, provide a clear picture of how effectively CRDL converts its operational activities into shareholder value.

In the context of the broader market, CRDL competes directly with industry leaders such as DTIL and RNAC. With a market capitalization of $112.58M, it holds a significant position in the sector. When comparing efficiency, CRDL's gross margin of N/A stands against DTIL's N/A and RNAC's 100.00%. Such benchmarking helps identify whether Cardiol Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Cardiol has consistently reported negative net income, with Q1 2026 showing a loss of -10,818,589 CAD. The gross profit has been zero for several quarters, indicating ongoing financial challenges.